SPARC/Sec/SE/2019-20/013 5th June 2019
To
BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.
BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001
Ref: Scrip Code: NSE: SPARC; BSE: 532872
Sub: Disclosure of Related Party Transactions – March 2019
Dear Sir/ Madam,
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure
Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party
Transactions on consolidated basis, in accordance with the applicable accounting standards,
for the half year ended March 31, 2019.
This is for your information and record.
Thanking you,
Yours faithfully,
For Sun Pharma Advanced Research Company Limited
Debashis Dey
Company Secretary
Encl: As above.
SUN ?1-l,L\RIVlA :~0 /t\f\ICED RESEARCH COIVIP,6,!\iY LIIVI ITED
Indian Accounting Standard (lnd AS-24) " Related Party Disclosures "
Names of related parties and description of relationship
1. Key Management Personnel
Dilip S. Shanghvi Chairman & Managing Director
Non Executive Director
Non-Executive Director
Independent Director
Sudhir V. Valia
Rajamannar Tennati
Bhavna Doshi
Ferzaan Engineer
Mark J. Simon
Independent Director (Additional Director w.e.f. May 5, 2017 and appointed as Independent Director w.e.f. August 5, 2017)
Independent Director (Additional Director w.e.f. May 5, 2.017 and appointed as Independent Director w.e.f. August 5, 2017)
2. Holding Company
Shanghvi Finance Private Limited
3. Enterprise under Significant Influence of Key Management Personnel (with whom transactions are entered)
Sun Pharmaceutical Industries Limited Aditya Imaging Information Technologies llP Family Investment Private Limited*
Sun Pharma laboratories Limited Alkaloida Chemical Company ZRT Virtuous Share Investment Pvt. ltd*
Sun Pharma Global FZE Ranbaxy (S.A.) (PTY) limited Quality Investment Private limited*
Sun Pharmaceutical Industries Inc.
Sun Pharmaceutical Medicare limited
Sun Pharmaceutical Industries Europe BV
Sun Petrochemicals Private limited
Bhavna Doshi & Associates llP
lnsite Vision Inc.
Taro Pharmaceuticals Inc.
Sun Farmaceutica Do Brasilltda
Taro Pharmaceuticals Industries limited
Sun Pharma Japan limited
• The above entities have amalgamated with Shanghvi Finance Private limited w.e.f. October 2.3, 2.018.
Particulars
Sun Pharmaceutical Industries Limited
Sale of services- License fees I Royalty on technology I R&D services
Purchase of goods (Net)
Purchase of fixed assets
Rent expense
Receiving of research and development services
Reimbursement of expenses paid
Reimbursement of expenses received
Sun Pharma laboratories limited
Sale of services- license fees I Royalty on technology I R&D services
Purchase of Goods
Sun Pharmaceutical Medicare limited
Purchase of Goods
SUrlPharma GIODafF2E
Sale of services- License fees I Royalty on technology I R&D services
Sun Pharmaceutical Industries Inc.
Sale of services- License fees I Royalty on technology I R&D services
Reimbursement I Receiving of research and development services
Purchase of goods
Sun Pharmaceutical Industries Europe BV
Purchase of goods
Reimbursement of expenses paid
Taro Pharmaceuticals Industries limited
Sale of services - R&D services
Receiving of research and development services
lnsite Vision Inc.
Sale of services- R&D services
Sun Phinma Japan limited
Purchase of goods
Virtuous Finance Private limited*
Viditi Investment Private Limited*
lakshwadeep Investments & Finance (P .) Limited
~In lakhs Half Year ended
March 31, 2019
1,2.2.7.78
(11.90)
0.44
101.47
42.2..27
32.1.32. 41.99
1,02.7.08
0.03
25.43
8,202..11
13.05 815.61
30.50
10.94
(0.49)
1.2.5
118.53
0.10
7.67
SUI\1 °H/- Rl\i!f-\. .!.\[li/1-\1\ICED i~ESEARCH :~Ofv i PAI'l " l_ i!VI ITF::D
'I: In Lakhs
Particulars Half year ended
March 31, 2019
Aditya Imaging Information Technologies LLP
Reimbursement of Expenses received 66.50
Bhavna Doshi & Associates LLP
Professional Charges 6.00
MarkJ. Simon
Receiving of research and development services 43.83
Lakshadeep Investments & Finance (P.) Limited
Issue of equity shares against conversion of warrants 2,475.00
Shanghvi Finance Private Limited
Issue of equity shares against conversion of warrants 12,525.00
Director Sitting Fees
Sudhir V. Valia 2.40 Bhavna Doshi 3.30
Rajamannar Tennati 1.50
Ferzaan Engineer 3.00
Mark Simon 3.00
Balance outstanding- Receivable I (Payable)
'I: in Lakhs
Particulars As at March 31,
2019
Sun Pharmaceutical Industries Limited 296.05
Sun Pharma Laboratories Limited 519.53
Sun Pharmaceutical Medicare Limited (31.45)
Aditya Imaging Information Technologies LLP 31.83
Sun Pharma Global FZE 132.12
Sun P.harmaceuticallndustries Inc. (2564.58)
Sun Pharmaceutical Industries Europe BV -
(48.22)
Taro Pharmaceuticals Industries Limited 1.5
Terms and condition of transactions with related parties.
The sale of services to related parties are made on terms equivalent to those that prevail in arms length transactions. Outstanding
balances at the year end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or
Chief Financial Officer
---·- -- ---- ----- ----- ------·- -----